Oncolys BioPharma Inc.
Notice of Submission of Clinical Trial Notification for Telomelysin, an Oncolytic Virus, for New Indication (Laryngeal and Pharyngeal Cancer)
A clinical trial notification for Telomelysin for laryngeal and pharyngeal cancer Phase 2 was submitted to the PMDA. Dosing is planned to start in the first half of 2027. The new indication aims to preserve vocal cord function. The company states the impact on fiscal 2026 year-end financials is minimal.
Key Figures
- Clinical trial notification submission: Submitted to PMDA
- Planned start of dosing: First half of 2027
- Target indication: Laryngeal and pharyngeal cancer
AI要約
Clinical Trial Notification Submission and Development Policy
Oncolys BioPharma Inc. has submitted a clinical trial notification to the PMDA for a Phase 2 clinical trial of Telomelysin (development code: OBP-301), an oncolytic virus, for a new indication targeting laryngeal and pharyngeal cancer. The company plans to establish a clinical trial network centered on research groups and aims to begin dosing in the first half of 2027.
Target Patients and Treatment Policy
The trial is a pilot study evaluating the efficacy and safety of concurrent radiotherapy and Telomelysin administration, targeting patients who are not candidates for surgical resection or chemoradiotherapy or who decline those options. The development concept emphasizes preservation of laryngeal and pharyngeal function under a new 'vocal cord preservation' strategy.
Oncolys BioPharma Inc.
Company overview · Stock price · Financial data · All IR
